Glenmark receives Orphan Drug Designation for GBR 1342

17 Sep 2019 Evaluate

Glenmark Pharmaceuticals has been granted Orphan Drug Designation by US Food and Drug Administration (USFDA) to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma who have received prior therapies.

Derived from the company’s proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology, GBR 1342 is being investigated for the treatment of multiple myeloma. The candidate is one of five clinical-stage assets in the pipeline of Glenmark’s new innovation company.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1968.55 -16.80 (-0.85%)
16-Dec-2025 11:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1787.30
Dr. Reddys Lab 1275.95
Cipla 1505.00
Zydus Lifesciences 920.45
Lupin 2087.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×